URGN stock icon

UroGen Pharma
URGN

$16.89
1.92%

Market Cap: 695M

 

About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Employees: 204

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 11 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 2 (+1) [Q1 2024]

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

27% more capital invested

Capital invested by funds: $321M [Q4 2023] → $407M (+$86.2M) [Q1 2024]

26% more call options, than puts

Call options by funds: $920K | Put options by funds: $728K

10.26% more ownership

Funds ownership: 69.34% [Q4 2023] → 79.61% (+10.26%) [Q1 2024]

7% more funds holding

Funds holding: 105 [Q4 2023] → 112 (+7) [Q1 2024]

14% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 36

Research analyst outlook

11 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$32
89%
upside
Avg. target
$50
196%
upside
High target
$60
255%
upside

11 analyst ratings

11 positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
255%upside
$60
Buy
Reiterated
1 Jul 2024
Ladenburg Thalmann
Matthew Kaplan
217%upside
$53.5
Buy
Maintained
14 Jun 2024
Oppenheimer
Leland Gershell
137%upside
$40
Outperform
Maintained
14 Jun 2024
HC Wainwright & Co.
Raghuram Selvaraju
255%upside
$60
Buy
Maintained
14 Jun 2024
Oppenheimer
Leland Gershell
89%upside
$32
Outperform
Maintained
14 May 2024

Financial journalist opinion